Vokuda Ramya S, B H Srinivas, Madhugiri Venkastesh S, Velusamy Saravana Kumar, Verma Surendra Kumar
Department of Pathology, Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Puducherry, India. Email:
Asian Pac J Cancer Prev. 2019 Feb 26;20(2):479-485. doi: 10.31557/APJCP.2019.20.2.479.
Background: Leptin, an adipocytokine functions via the leptin receptor, OB-Rb that contains an intact intracellular domain and activates the JAK/STAT signalling cascade. It stimulates growth, migration and invasion of cancer cells in vitro potentiating angiogenesis. Recently, the involvement of leptin in tumor progression is being explored. Gliomas exhibit poor prognosis, low survival rates demanding for novel therapeutic regimens resulting in discovery of many potential biomarkers and pharmaceutical targets. We analysed the potential role of leptin and OB-Rb in carcinogenesis of malignant gliomas. Methods: Sixty fresh tissue samples of diffuse gliomas were collected after tumor excision. Real time PCR, immunohistochemical (IHC) analysis and western blot analysis were carried out to assess the expression of leptin and its receptor. Results: The present study demonstrates the expression of leptin and LepR and their involvement in tumor progression. Of the 60 cases, 57 cases (95%) and 53 cases (88.3%) showed amplification for leptin and OB-Rb respectively. The expression of these proteins were measured semi-quantitatively and correlated with degree of malignancy (p<0.05). The bands were visualised on western blot. Conclusion: Leptin may be valued as a pharmaceutical target and anti-leptin compounds could be developed as drugs in mono- or combined therapies for these tumors.
瘦素是一种脂肪细胞因子,通过瘦素受体OB-Rb发挥作用,该受体含有完整的细胞内结构域并激活JAK/STAT信号级联反应。它在体外刺激癌细胞的生长、迁移和侵袭,增强血管生成。最近,人们正在探索瘦素在肿瘤进展中的作用。胶质瘤预后较差,生存率低,需要新的治疗方案,从而发现了许多潜在的生物标志物和药物靶点。我们分析了瘦素和OB-Rb在恶性胶质瘤致癌过程中的潜在作用。
肿瘤切除后收集60份弥漫性胶质瘤新鲜组织样本。进行实时PCR、免疫组织化学(IHC)分析和蛋白质印迹分析以评估瘦素及其受体的表达。
本研究证实了瘦素和瘦素受体的表达及其与肿瘤进展的关系。60例病例中,分别有57例(95%)和53例(88.3%)显示瘦素和OB-Rb扩增。这些蛋白质的表达进行半定量测定,并与恶性程度相关(p<0.05)。在蛋白质印迹上观察到条带。
瘦素可作为药物靶点,抗瘦素化合物可开发为单药或联合治疗这些肿瘤的药物。